humulin r
eli lilly do brasil ltda - insulina humana - antidiabeticos
novolin r
novo nordisk farmacÊutica do brasil ltda - insulina humana - antidiabeticos
caninsulin® 40 ui/ml
merck sharp & dohme saÚde animal ltda - insulina; - hormÔnios/similares
visulin n
ems s/a - insulina isofana - antidiabeticos
prozinc 40 ui/ml suspensão injetável para cães
boehringer ingelheim vetmedica gmbh - insulina humana 40.0 ui - suspensão injetável - insulina (humana) - cães
levemir
novo nordisk farmacÊutica do brasil ltda - insulina detemir - antidiabeticos
solumarv
marvel lifesciences ltd - insulina humana - diabetes mellitus - tratamento da diabetes.
galvus
novartis europharm limited - vildagliptina - diabetes mellitus, tipo 2 - drogas usadas em diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.
jalra
novartis europharm limited - vildagliptina - diabetes mellitus, tipo 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 e 5. 1 para dados disponíveis em diferentes combinações).
xiliarx
novartis europharm limited - vildagliptina - diabetes mellitus, tipo 2 - drogas usadas em diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 e 5. 1 para dados disponíveis em diferentes combinações).